Evidence map›Paper›PMID 31161572›Full record

Observational studyJournal of general internal medicine2019

Prescription Medications for the Treatment of Insomnia and Risk of Suicide Attempt: a Comparative Safety Study.

Jill E Lavigne, Kwan Hur, Cathleen Kane, Anthony Au, Todd M Bishop, Wilfred R Pigeon

Open access · bronzeAbstract readComparative StudyObservational Study
In one paragraph

Observational study in Journal of general internal medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Prescription medications for insomnia are associated with suicidal thoughts and behaviors in two nationally representative samples.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2021
    Article
  12. Sleep Disturbances and Atopic Dermatitis: Relationships, Methods for Assessment, and Therapies.The journal of allergy and clinical immunology. In practice · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Jill E LavigneCenter of Excellence for Suicide Prevention, Canandaigua VA Medical Center, Canandaigua, NY, USA. jill.lavigne@va.gov.
Kwan HurVA Center for Medication Safety, Hines, IL, USA.
Cathleen KaneCenter of Excellence for Suicide Prevention, Canandaigua VA Medical Center, Canandaigua, NY, USA.
Anthony AuVA Center for Medication Safety, Hines, IL, USA.
Todd M BishopCenter of Excellence for Suicide Prevention, Canandaigua VA Medical Center, Canandaigua, NY, USA.
Wilfred R PigeonCenter of Excellence for Suicide Prevention, Canandaigua VA Medical Center, Canandaigua, NY, USA.
Canandaigua VA Medical Center · USMedication Management (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

importanceGuidelines for the pharmacological treatment of chronic insomnia in adults recognize that trazodone and other off-label medications are commonly prescribed despite poor evidence. The Department of Veterans Health Affairs (VA) fills high volumes of inexpensive, over-the-counter sedating antihistamines and older antidepressants in addition to benzodiazepines and zolpidem. Yet little is known about the comparative safety of these agents with regard to suicidal behavior.

objectivesTo assess the comparative effectiveness of the safety of medications routinely used to treat insomnia in VA.

designComparative effectiveness using propensity score-matched samples.

settingVA.

participantsVA patients without any history of suicidal ideation or behavior 12 months prior to first exposure. EXPOSURES: VA formularies and data were used to identify prescriptions for insomnia. Agents accounting for at least 1% of total insomnia fill volume were < 200 mg trazodone, hydroxyzine, diphenhydramine, zolpidem, lorazepam, diazepam, and temazepam. Exposure was defined as an incident monotherapy exposure preceded by 12 months without any insomnia medications. Subjects with insomnia polypharmacy or cross-overs in the 12 months following first exposure were excluded. MAIN OUTCOMES AND MEASURES: Suicide attempts within 12 months of first exposure.

resultsThree hundred forty-eight thousand four hundred forty-nine subjects met criteria and three well-balanced cohorts by drug class matched to zolpidem were created. After adjusting for days' supply, mental health history, and pain and central nervous system medication history, hazard ratios (compared to zolpidem) were as follows: (< 200 mg) trazodone (HR = 1.61, 95% CI 1.07-2.43); sedating antihistamines (HR = 1.37, 95% CI 0.90-2.07); and benzodiazepines (HR = 1.31, 95% CI 0.85-2.08). CONCLUSIONS AND RELEVANCE: Compared to zolpidem, hazard of suicide attempt was 61% higher with trazodone (< 200 mg). No significant differences in suicide attempt risk were identified between benzodiazepines or sedating antihistamines and zolpidem, respectively. These findings provide the first comparative effectiveness evidence against the use of trazodone for insomnia.

Indexed as

AdultFemaleHumansMaleMiddle AgedOff-Label UseRisk AssessmentSleep Aids, PharmaceuticalSleep Initiation and Maintenance DisordersSuicide, AttemptedTrazodoneVeteransYoung AdultZolpidemSleep Aids, PharmaceuticalTrazodoneZolpidemantihistaminesbenzodiazepinescomparative safetydrughypnoticsinsomniamedicationpharmacotherapysuicidal behaviorsuicidesuicide attempttrazodoneVeteranzolpidem

Identifiers

PMID31161572
PMCPMC6667726
OpenAlexW2948073973

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.